CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
LY317615drug
Likely dose
LY317615 500 mg orally once dailyAI-extracted
Key inclusion· 3
  • ✓Diagnosis of recurrent or refractory DLBCL
  • ✓Adequate organ functions
  • ✓Able to swallow capsules
Key exclusion· 2
  • ✕More than 3 prior treatments for DLBCL
  • ✕Serious heart problems

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00042666
NCT00042666Phase 2Completed
CompareCT.gov

A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company·interventional·Posted Aug 6, 2002·Updated Aug 10, 2020

In Brief

A Phase 2 clinical trial evaluating LY317615 for Non-Hodgkin's Lymphoma. Completed, enrolled 55 participants across 3 sites.

Detailed Summary

This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 6, 2002
Enrollment StartJun 1, 2002
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 23.9 years ago

Interventions

LY317615drug

500 mg, oral, QD, up to six 28 day cycles